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ABSTRACT
Objective: The main aim was to develop a modified oral chronotropic system for timed release tramadol hydrochloride (tramadol HCl). Biological 
rhythms are highly organized for all functions of the human body both in health and in disease. Hence, drug delivery systems were designed to make 
possible the treatment of illness based on biological rhythms for improving therapeutic efficacy.
Materials and Methods: These systems consist of immediate release core tablet of tramadol HCl using different materials such as SSG, crospovidone, 
pregelatinized starch and then coated with Tamarindus gum, hydroxypropyl methylcellulose (HPMC), and their combination. This coated tablet is 
enteric coated with Eudragit L 100, Eudragit S100 to produce lag time period of 5 h.
Results: Immediate release systems are optimized with formulation F6 containing pregelatinized starch as an immediate release agent, the formulation 
is coated with Tamarindus gum, HPMC, and their combination. The release retardant behavior of Tamarindus gum was evaluated in compressed 
coated formulations. This coated tablet is enteric coated with Eudragit L 100, Eudragit S100 to release the drug after the lag time period of 5 h.
Conclusion: A modified oral chronotropic system for timed release of tramadol HCl was made possible with the compressed coated tablets CF3 which 
shows better drug release followed by enteric coating with Es c coat fulfilled our objective of work.
Keywords: Rheumatoid arthritis, Chronotropic delivery, Tramadol HCl, Biological rhythms.
INTRODUCTION
Rheumatoid arthritis is an inflammatory condition affecting synovial 
joints severely. Arthritic pain affects millions of people worldwide [1,2]. 
Nonsteroidal anti-inflammatory drugs are commonly used to treat the 
rheumatoid arthritis pain. They help to manage pain, inflammation, and 
swelling at the relevant area of rheumatoid arthritis [3]. Opioids are 
powerful pain-relieving substances which range from relatively mild 
(codeine) to strong (morphine). Examples of weak opioids are codeine 
and tramadol. Examples of strong opioids are oxycodone, morphine, 
and fentanyl [4,5].
Chronotherapeutics refers to treatment for a disease which is timed to 
match the biological rhythms of that disease to optimize the therapeutic 
benefits and minimize side effects by increasing in vivo bioavailability. 
The benefits of chronotherapeutics have been very helpful in the 
management of a number of diseases. They have a potential role in 
chronotherapy which benefits the patients suffering from allergic 
rhinitis, rheumatoid arthritis, and related disorders, asthma, cancer, 
cardiovascular diseases, and peptic ulcer disease [6,7].
Tramadol HCl is a synthetic centrally acting amino-cyclohexyl analgesic 
that acts as an opioid agonist with selectivity for μ receptor which is 
treated like the drug of choice and an effective agent for moderate to 
severe pain. It is having good oral bioavailability and adequate colon 
absorption [8]. Tramadol HCl has a special role in treating rheumatoid 
arthritis, which had apparent circadian rhythms and shows peak 
symptoms in the early morning [9,10]. The HCl salt of tramadol is a 
widely used narcotic analgesic for severe pain.
MATERIALS AND METHODS
Tramadol HCl was obtained from Hetero labs, Hyderabad, Sodium 
Starch Glycolate, crospovidone, pregelatinized starch, HPMCK100, 
Eudragit L100, and Eudragit S100 were obtained from yarrow chem 
products. Microcrystalline cellulose, magnesium stearate, Talc, and all 
other reagents were of analytical grade. Tamarindus gum was extracted 
by a suitable analytical procedure given below.
Compatibility studies by Fourier-transform infrared spectroscopy 
(FTIR)
Active drug blended with individual excipients taken in 1:0.5 and 
1:1 ratio. It was filled in closed vials and placed in the refrigerator 
and open workbench. The drug-excipient compatibility studies were 
done by FTIR, i.e., using Kerr pellet method. Samples were observed 
under Bruker FTIR scanned in the wavelength region between 400 and 
4000 cm−1. The spectra were analyzed and interpreted in Figs. 1 and 2.
Calibration curve for tramadol Hcl
100 mg of tramadol HCl was taken in a 100 mL volumetric flask 
and dissolved with 100 mL of 0.1 N HCl to give the concentration of 
1000 µg/mL. From the above stock solution, aliquots of concentrations 
40–300 µg/mL were prepared for pH 1.2 buffer and concentrations 
20–160 µg/mL were prepared for pH 7.4 buffers. When this solution 
was scanned in the ultraviolet (UV) range, i.e., from 200 nm to 800 nm 
λmax was found to be 271 nm for tramadol HCl. The absorbance of these 
solutions was measured at 271 nm and a graph of concentration versus 
absorbance was plotted and are shown in Figs. 3 and 4.
Isolation of Tamarindus gum
Take the tamarind seeds and peel out the outer cover and obtain the 
white part of seeds and crush them. The crushed seeds of Tamarindus 
were soaked in water for about 24 h, then take this soaked crushed seeds 
into a muslin cloth and press them for the release of gum. The marc 
was removed from the gum and to the extracted gum equal quantity 
of absolute ethyl alcohol was added to precipitate the gum, and it was 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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separated by filtration. The marc was for multiple extractions with 
decreasing quantity of extracting solvent i.e., water with the increase 
of the number of extractions. The isolation process was continued until 
the material was free of gum. The separated gum was dried in a hot air 
oven at temperature 40°C. Then, the extracted dried gum was powdered 
and stored in an airtight container at room temperature [11,12].
Purification and standardization of gum
Loss on drying
The 5 g gum was dried at 105°C ± 5°C till the constant weight of gum 
was obtained. The loss on drying was found to be <7% w/w.
Ash value
1 g of gum was accurately weighed and evenly distributed it in the 
crucible. It was dried at 105°C for 1 h and ignited in a muffle furnace 
at 700°C ± 25°C. Percentage of ash content was found to be <6% w/w.
pH
The binder gum is natural and has a pH between 7.0–7.5.
This gum was also tested for flow properties as per I. P. and shown in 
Table 1 [12].
Swelling property of mucoadhesive materials
Natural mucoadhesive material obtained from the fruits of Tamarindus 
indica is nontoxic. 250 mg of Tamarindus indica gum was allowed to 
hydrate in 25 ml of distilled water at 25°C in a 25 ml graduated cylinder 
and volume measured at 5 min. Intervals until there was no further 
hydration observed. The swelling property was determined at different 
time intervals (Table 2) [13,14].
Formulation development of immediate release core tablet
Tramadol HCl and all other ingredients listed in Table 1 were collected. 
Except for magnesium stearate and talc remaining ingredients was 
passed through sieve no 60 to get uniform sized particles and weighed 
accurately. Finally, magnesium stearate and talc (passed through a Wsh) 
were introduced to the powder mixture. The final mixture was shaken 
manually for 5–10 min. This powder was passed through the hopper 
of 16 station rotary tableting machine and punched into tablets using 
6 mm punch by direct compression method. This process is similar for 
all core formulations.
Formulation development of compression coat tablet
The core tablets were compression coated with the coating mixture 
given in Table 2. All the constituents of the coating mixture consisting 
of HPMC alone, HPMC, and Tamarindus gum in the ratios of 3:1, 
1:1, and 1:3 were uniformly mixed together and then used for the 
compression coating. MCC was added for its cushioning effect so as 
to protect the core tablet from any damage during the compression 
coating procedure. To prepare compression-coated tablets of 
crushing strength of about 6 kg, one-third of the powder was placed 
in 8-mm die, the core tablet was placed centrally, and the remaining 
two-third of powder was placed over it in the die cavity and finally 
compressed using 8-mm punch to obtain the compression coated 
tablets [15,16].
Table 1: Flow properties of dried tamarind gum
S.No. Parameter Value
1 Bulk density (g/cm3) 0.45±0.8
2 Tapped density (g/cm3) 0.32±0.2
3 Carr’s index (%) 24.5±0.24
4 Angle of repose (0) 26.0±0.22
Number of experiments (n)=3
Table 2: Swelling property of Tamarindus indica gum
S.No. Time interval Swelling property (mL)
1 After 5 min 0.8
2 After 10 min 1.0
3 After 15 min 1.1
4 After 20 min 1.3
5 After 25 min 1.4
6 After 30 min 1.5
Fig. 3: Calibration curve of tramadol HCl at pH 1.2
Fig. 4: Calibration curve of tramadol HCl at pH 7.4
Fig. 1: IR spectrum of pure tramadol HCl
Fig. 2: IR spectrum of tramadol HCl with polymers
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Formulation development of enteric coated tablet
The compressed core tablets were then coated with enteric polymers 
such as Eudragit L-100 and Eudragit S-100 until the compressed core 
tablets percentage total weight gain (%TWG) of 5, 10, 15, and 20% 
were obtained. Their compositions and respective formulation codes 
are given in Tables 3 and 4.
Evaluation parameters 
Pre-compressional parameters
The flow properties of powder blends were evaluated by determining 




The weight variation test is carried out to detect the uniformity in 
the weight of tablets. First, the total weight of 20 tablets from the 
randomly selected formulations is determined, and the average weight 
is calculated. The individual weight of each tablet is also determined. 
Then, the weight variation is calculated by the below formula [15].
% wt variation =  (average weight of tablet-weight of each tablet/
average of tablet) *100.
Hardness and friability
For each formulation, the hardness of at least three tablets was 
determined using Monsanto hardness tester, an average is calculated. 
Friability represents the mechanical strength of tablets. Roche 
friabilator was used to determine the friability by rotated at 25 rpm 
for 100 rotations. After the test, tablets were reweighed; percentage 
friability from the loss in the weight is calculated by the following 
expression.
% Friability = ([Initial weight– Final weight]/Initial weight) 100
Lag time of coated tablets
The intention of developing the pulsatile tablets was to release the drug 
at a predetermined time period for suitable therapeutic benefit. Hence, 
enteric polymers were used for this purpose, which shows variations in 
lag time with different compositions and the time at which drug release 
starts is noted as its lag time.
Drug content
For the determination of the content uniformity test, ten tablets were 
weighed, powdered, and the powder equivalent to 100 mg of tramadol 
HCl was extracted into methanol. Then, the drug content was estimated 
by measuring the absorbance value after suitable dilution in methanol. 
For this determination standard calibration curve of tramadol 
HCl is used. Then, average drug content is calculated by taking six 
determinations each [17].
In vitro drug release study of core tablet
In vitro drug release studies for the prepared compressed coat tablet 
were studied using USP II apparatus, by taking 900 ml of dissolution 
medium initially by pH 1.2 HCl for 2 h and then replaced by 900 ml of pH 
7.4 phosphate buffer and the shaft is rotated at 50 RPM. At an interval 
of 1 h, 5 ml aliquots were withdrawn. These are withdrawn from a zone 
at the midway of dissolution medium and the top of the rotating paddle 
should not be <2 cm apart from the bottom of the vessel. Suitable sink 
conditions were maintained throughout the dissolution process. Every 
time the samples were filtered through Whatman filter paper no 4, the 
UV absorbance was measured at 271 mm using (UV1700–Shimadzu) 
spectrometer after diluting with appropriate dissolution medium. The 
concentrations of tramadol HCl were determined from the standard 
calibration curves. This in vitro dissolution study was performed for a 
period of up to 12 h [18].
RESULTS AND DISCUSSION
The aim of present work is to formulate compression coated matrix 
tablet and then enteric coated with Eudragit S 100 and Eudragit L 100 
for site-specific delivery of tramadol HCl for timed release. The use of 
enteric polymer Eudragit S 100 coated matrix tablets makes them able 
to release the drug at the particular pH of the colonic fluid.
Properties of Tamarindus gum
In this study, Tamarindus gum was extracted as stated above and the 
flow properties of the gum are reported in Table 1, which were within 
limits and have shown good flow properties. As it is natural gum, its 
swelling properties were also studied and they were reported in Table 
2, which shows swelling of 1.5 mL in measuring cylinder at the end of 
30 min which represents good swelling as well as good mucilage nature 
of gum. Finally, chemical tests were conducted where the values were 
represented in Table 3, which shows that the gum is having recognizable 
quantities of carbohydrates, alkaloids, and glycosides. The gum was 
proved as mucilage by ruthenium red test, and it was also having pH 
in the range of 7 to 8. After the identification of gum to optimize the 
release retarding efficiency of gum, it was combined with HPMC in 
different percentage proportions (75:25, 50:50, and 25:75).
Pre-formulation studies
FTIR analysis shows that the drug tramadol HCl compatible with the 
polymers used. There was no drug-excipients interaction in the physical 
mixture. It also suggests that the drug did not undergo any degradation 
or interaction through the whole of the coating process.
The method employed for tableting in this study was first focused 
on direct compression technique for which the powder blend should 
possess good flow. The optimum value for Carr’s index (%) is up to 
15%. Values for the angle of repose (θ) ≤25 generally indicate free-
flowing material. By means of pilot studies, it was found that pure 
tramadol HCl exhibited an angle of repose value of 23.21 ± 0.52 
Table 4: Formulation of an immediate release core tablet
Ingredients F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) F6 (mg) F7 (mg) F8 (mg) F9 (mg)
Tramadol HCl 100 100 100 100 100 100 100 100 100
SSG 6 - - 8 - - 10 - -
Crospovidone - 6 - - 8 - - 10 -
Pregelatinized starch - - 6 - - 8 - - 10
Microcrystalline cellulose 41 41 41 39 39 39 37 37 37
Magnesium stearate 1 1 1 1 1 1 1 1 1
Talc 2 2 2 2 2 2 2 2 2
The total weight (mg) 150 150 150 150 150 150 150 150 150
Table 3: Chemical tests for Tamarindus gum
S.No. Tests Observation
1 Carbohydrates (Molisch’s test) +
2 Tannins (Ferric Chloride test) -
3 Proteins (Ninhydrin test) -
4 Alkaloids (Wagner’s test) +
5 Glycosides (Keller–Killani test) +
6 Mucilage ( Ruthenium red test) +
+: Present, -: Absent
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indicating good flow property. It was further supported by high Carr’s 
index value of 17.24 ± 0.27. All these values are reported in Table 5. 
The tablet powder blend possessed good flow properties. The flow 
properties of the powder mixture are helpful in the maintenance of the 
uniformity of dose in the formulations of tablets. The tablets of different 
batches showed varied thickness (2.56 ± 0.1–2.70 ± 0.2) and hardness 
(4.0 ± 0.45 kg/cm3–6.4 ± 0.29). The friability (0.12%–0.78%) and weight 
variation (%deviation: 99.5 ± 1.36–101.35 ± 1.63) of different batches 
of tablets are reported in Table 6 and found within the prescribed 
limits. The drug content was found to be uniform within the batches, 
and it is also found that it is above 98% of different tablet formulations. 
The evaluation of the release profile is recommended as an important 
tool in the development and optimization of drug formulations. Release 
studies of core tablet were carried out in pH 7.4 phosphate buffer [17]. 
Among the core tablets, the formulation containing crospovidone in 
high concentration as formulation code F8 releases the drug within 30 
min and that formulations containing a high concentration of Sodium 
Starch Glycolate and pregelatinized starch with formulation code 
F7 and F9 release the maximum drug within 45 min. These data are 
reported in Table 7 and Fig. 5.
The second part of the formulation focused on the release retarding 
agents such as HPMC and isolated Tamarindus gum at different 
ratios which were reported in Table 8 and in the third part, it was 
focused on the pH-dependent polymeric coating of the tablets. The 
coating polymers were, Eudragit S-100 and Eudragit L-100, dissolves 
above pH 7.0 and pH 6, respectively, thereby protecting the drug 
from releasing from the core before reaching the colonic region. The 
coating composition and achieved thickness in the form of %TWG 
values are represented in Tables 9 and 10. Use of Eudragit polymers 
will be useful in colon targeting of drug or otherwise, it avoids the 
wastage of drug, and it helps in the chronotropic release of tramadol 
HCl to treat rheumatoid arthritis. Once the enteric coating dissolves, 
it is expected that drug release would be by HPMC and a combination 
of gum.
For this purpose dissolution was carried out in two different media. 
6% of Eudragit S 100 and Eudragit L 100 are enteric coated to achieve 
5, 10, 15, and 20% weight gain separately. These values are reported 
in Table 10. The weight variation, hardness, and the drug content of 
all the formulations were found to be within the official limit. From 
the dissolution data, it was observed that all the formulations showed 
little or no significant release at pH 1.2 (i.e., <1% drug release). 
Release started in pH 7.4 buffer for all the formulations. Beyond this 
CF1 to CF4 were also studied and their drug release was represented 
in Fig. 6 This may be attributed to the fact that the threshold pH 
(pH at which dissolution occurs) of Eudragit L-100 is 6. The lag 
time for drug release in pH 6.8 buffer was found to be dependent on 
Table 7: Percentage drug release studies of core tablets
Time (min) F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
5 26.8±1.22 28.5±1.40 28.5±1.4 32.8±1.22 34.5±1.40 34.8±1.25 36.8±1.22 38.5±1.40 38.8±1.25
10 47.96±1.43 52.23±1.58 35.6±1.61 50.96±1.43 54.23±1.58 47.6±1.30 53.96±1.43 56.23±1.58 57.6±1.30
15 68.13±1.58 70.43±1.24 55.6±1.20 70.13±1.58 73.43±1.24 58.3±1.34 72.13±1.58 76.43±1.24 75.3±1.34
30 81.6±1.48 86.4±1.58 78.2±1.46 84.6±1.48 88.4±1.58 80.7±1.48 86.6±1.48 99.8±1.58 89.7±1.48
45 92.6±1.58 98.6±1.52 87.8±1.36 96.6±1.58 99.6±1.52 90.21±1.47 99.6±1.58 - 99.21±1.47
60 101.4±1.80 - 92.65±1.56 - - 98.2±1.48 - - -
Values are expressed as mean±SD (n=3) for all the samples. SD: Standard deviation
Table 5: Characterization of the tablet powder blend
Formulation code Mean±SD (n=3)
Bulk density (g/ml) Tapped density (g/ml) Hausner’s ratio Carr’s index (%) Angle of repose (θ)
F1 0.541±0.11 0.691±0.12 1.276±0.45 16.62±0.52 340±0.27
F2 0.484±0.13 0.615±0.16 1.271±0.48 14.30±0.48 330±0.25
F3 0.710±0.14 0.873±0.14 1.251±0.38 12.714±0.48 310±0.21
F4 0.712±0.11 0.870±0.10 1.206±0.32 15.126±0.50 320±0.28
F5 0.718±0.16 0.871±0.14 1.223±0.45 14.513±0.46 300±0.18
F6 0.410±0.14 0.483±0.16 1.178±0.16 15.113±0.48 320±0.24
F7 0.420±0.11 0.462±0.12 1.131±0.24 15.010±0.42 350±0.26
F8 0.541±0.12 0.691±0.14 1.276±0.32 11.62±0.46 340±0.24
F9 0.450±0.14 0.585±0.12 1.300±0.42 13.07±0.42 310±0.27
SD: Standard deviation
Table 6: Characterization of compressed core tablet
Formulation 
code









F1 101±1.12 6.4±0.32 0.72 2.6±0.21 99.28±1.36 3.1±0.24
F2 97±1.16 6.3±0.24 0.68 2.6±0.24 97.16±1.24 2.6±0.26
F3 98±1.14 5.8±0.24 0.69 2.7±0.26 101.1±1.28 2.4±0.18
F4 99±1.11 5.6±0.26 0.66 2.75±0.24 97.68±1.16 2.7±0.22
F5 98±1.20 5.7±0.32 0.68 2.6±0.12 99.41±1.36 2.3±0.16
F6 99±1.12 6.4±0.28 0.65 2.62±0.16 98.19±1.28 1.4±0.12
F7 97±1.13 4.0±0.32 0.12 2.6±0.12 102.6±1.12 19.0±0.24
F8 100±1.12 4.5±0.26 0.78 2.56±0.12 99.5±1.24 17.2±0.24
F9 98±1.16 6.4±0.24 0.70 2.59±0.16 99.6±1.28 21.3±0.26
SD: Standard deviation
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the level of coating 5%, 10%, 15%, and 20% (coating level in TWG) 
corresponding to batches EL a, EL b, EL c, and EL d, respectively, 
showed significant drug release (i.e., >20%) after a lag time of 5 h. 
Formulations coated with ES-100 TWG 15% and 20% showed no 
release in pH 7.4 buffer (i.e., <1% drug release). However, the release 
for formulations coated with ES 100 TWG 5%, 10% started in 7.4 
buffer. Furthermore, the lag time for drug release in pH 6.8–7.4 buffer 
was found to be dependent on the level of coating. 5, 10, 15, and 20% 
(coating level in TWG) corresponding to batches ES a, ES b, ES c, and 
ES d showed significant drug release (i.e., < 25%) after a lag time 
of 5 h (in pH 7.4 medium). Drug release in pH 7.4 buffer is > 90% 
for ES a, ES b in 10 h, >90% for ES c in 12 h, and <90% for EL d 
in 10 h. Formulation ES c coated with 15% TWG of Eudragit S-100 
showed the most desirable properties. These values are reported in 
Table 11. Hence, ES c was considered as the optimized formulation 
for colonic drug delivery. Taking into account the dissolution profile 
of tramadol HCl compressed coated tablets, the CF3 was an optimized 
formulation as its dissolution profile was according to the expected 
requirements of the study [19].
The release mechanism is influenced by porosity and tortuosity of 
the matrix. Release kinetics was further fitted with different kinetic 
models, zero-order, first-order, Higuchi, or Korsmeyer–Peppas. Among 
these zero-order and Peppas plots are represented in Figs. 7 and 8. 
The drug release kinetics data was reported in Table 12 According 
to the observed values, ES c formulation was best fitted with a 
zero-order model indicating their release kinetics is not dependent 
on the concentration of the drug. The drug release data were fitted 
to the Korsmeyer–Peppas equation. In this study, the tramadol HCl 
release, in neutral medium, from Tamarindus gum tablets showed 
a good fit into the Korsmeyer–Peppas equation, indicating the 
combined effect of diffusion and erosion mechanisms for drug release. 
It exhibited a correlation coefficient (r2) >0.98. If the values are, 
0.45< n corresponds to a Fickian diffusion mechanism, and n = 0.89 
indicates a purely relaxed controlled delivery which is referred to as 
Case II transport. Intermediate values 0.45< n < 0.89, which indicate 
Table 9: Composition of coating solution
Ingredient Amount/100 mL
Eudragit L 100/S 100 (g) 6
Triethyl citrate (mL) 2
Isopropyl alcohol (mL) 100
Talc (g) 2
Table 10: Percentage composition of coating solution with 
formulation code









5 EL a 5 ES a
10 EL b 10 ES b
15 EL c 15 ES c
20 EL d 20 ES d
Fig. 5: %Drug release of F1 to F9
Fig. 6: % Drug release of CF1 to CF4
Fig. 7: Zero-order release of CF3 with ESc coat
Fig. 8: Korsmeyer’s Peppas plot of CF3 with Esc coat
Table 8: Formulation development of compression coated tablet
S.No Ingredients CF1 CF2 CF3 CF4
1 HPMC 400 300 200 100
2 Tamarindus gum 0 100 200 300
HPMC: Hydroxypropyl methylcellulose
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an anomalous behavior (Non-Fickian kinetics with the mechanism of 
coupled diffusion/polymer relaxation). The values of n > 0.89 have 
been observed, which has been regarded as Super Case II kinetics. The 
mechanisms of drug release are (super case-II) since they fitted well 
with Korsmeyer–Peppas models as their r2 values in the range of 0.999 
with n value above 1. This indicates that the drug release depends on 
swelling, relaxation, and erosion of polymer and also follows zero-
order release kinetics [20].
CONCLUSION
A successful chronotropic drug delivery requires that the suitable 
release mechanism in the delivery system only respond to the 
biological conditions such as variation in pH particular to the colon. 
Due to the lack of discontinuity in physiological parameters along the 
GI tract, few mechanisms can be incorporated into a delivery system 
to effect in this type of drug release, among them site-specific drug 
delivery was selected. Here, the use of Tamarindus gum as release 
retardant has special benefits in combination with HPMC in case of 
rheumatoid arthritis treatment to obtain desired lag time. A modified 
oral chronotropic system for timed release of tramadol HCl was made 
possible with the compressed coated tablets CF3 which shows better 
drug release followed by enteric coating with Es c coat fulfilled our 
objective of work.
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